AluOmics: Sequencing-free Neoantigen Discovery

The problem of optimal target selection represents a critical tension in the provision of targeted immunotherapy for many cancer types. Tumor-associated antigens (TAA) are widely shared and boast broad applicability for many patients; however, concerns abound over their efficacy and safety in cancer vaccine formulations since these targets are expressed in non-cancerous cells. Separately, the employment of preferred tumor-specific mutation-derived “neoantigens” in immunotherapy is burdened by a costly and time-intensive discovery process in which sequencing of patient samples reveals potentially actionable targets. As a result, there is a pressing need for cost-efficient methods to rapidly identify tumor-specific antigens that are widely shared among cancer types as molecular targets in the immunotherapy armamentarium. This proposal articulates one such method, leveraging insights derived from large-scale computational interrogation of cancer genomics data to explore the pan-cancer phenomenon of transposable element dysregulation.

AluOmics is developing a patent-pending, low-cost, rapid method by which a given tumor’s targetable neoantigen repertoire can be profiled without the need for costly and time-intensive sequencing. This technique aspires to uncouple the need for tumor-sequencing from vaccination, thus eliminating one of the largest logistical barriers to widespread implementation of this promising immunotherapeutic modality.

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on reddit

The Idea Bouncer:

Contact the Idea Bouncer:

  • Hidden
Scroll to Top

Login to the IdeaBounce®